<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955604</url>
  </required_header>
  <id_info>
    <org_study_id>TVP-1012/PM102 CR</org_study_id>
    <nct_id>NCT00955604</nct_id>
  </id_info>
  <brief_title>Azilect + Antidepressant Chart Review</brief_title>
  <acronym>STACCATO</acronym>
  <official_title>Investigation of the Occurrence of Serotonin Toxicity in Parkinson's Disease (PD) Patients Treated Concomitantly With Rasagiline and Antidepressants, Using Retrospective Chart Review</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify the occurrence of serotonin toxicity in Parkinson's Disease (PD) patients&#xD;
      receiving antidepressant therapy and rasagiline, compared to those receiving rasagiline&#xD;
      without antidepressant medications and compared to PD patients receiving antidepressants, but&#xD;
      not rasagiline.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency of serotonin toxicity, as determined by the Adjudication Committee will be calculated for each Group. The primary comparison will be Group R+AD vs. Group R and vs. Group AD</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Serotonin Syndrome</condition>
  <arm_group>
    <arm_group_label>Group R+AD</arm_group_label>
    <description>Group R+AD Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) for at least 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group R</arm_group_label>
    <description>At least 2 months of rasagiline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group AD</arm_group_label>
    <description>At least 2 months of Anti-PD and Rasagiline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group R+AD Rasagiline + Antidepressant</intervention_name>
    <description>Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days</description>
    <arm_group_label>Group R+AD</arm_group_label>
    <other_name>Azilect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group R Rasagiline</intervention_name>
    <description>At least 2 months of rasagiline</description>
    <arm_group_label>Group R</arm_group_label>
    <other_name>Azilect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group AD Anti-PD + Antidepressant</intervention_name>
    <description>An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.</description>
    <arm_group_label>Group AD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patients with a diagnosis of PD:&#xD;
&#xD;
          -  who received rasagiline at any dose, as mono- or adjunct therapy for PD, with&#xD;
             concomitant antidepressant medication, OR&#xD;
&#xD;
          -  who received rasagiline at any dose, as mono- or adjunct therapy for PD, without&#xD;
             concomitant antidepressant medication, OR&#xD;
&#xD;
          -  who received antidepressant medication and any other dopaminergic anti-PD therapy&#xD;
             besides rasagiline or selegiline including dopaminergic agents, anticholinergics,&#xD;
             amantadine, deep brain stimulation (DBS), pallidotomy, etc.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients with a diagnosis of PD&#xD;
&#xD;
          2. Rasagiline treatment as mono- or adjunct therapy for PD with concomitant&#xD;
             antidepressant medication (SSRIs, SNRIs, St. John's wort and/or TCAs) at any time&#xD;
             during the specified review period, OR Rasagiline treatment as mono- or adjunct&#xD;
             therapy for PD without concomitant antidepressant medication (SSRIs, SNRIs, St. John's&#xD;
             wort and/or TCAs) at any time during the specified review period. OR Antidepressant&#xD;
             therapy (SSRIs, SNRIs, St. John's wort and/or TCAs) and any other dopaminergic anti-PD&#xD;
             treatment besides rasagiline or selegiline at any time during the specified review&#xD;
             period&#xD;
&#xD;
          3. Willing to consent to review of office chart and to review of records of ER visits&#xD;
             and/or hospitalizations corresponding to the review window, if required&#xD;
&#xD;
          4. Patients previously participating in a rasagiline clinical trial (and their follow-up&#xD;
             protocols) are eligible, provided that they did not receive antidepressant therapy&#xD;
             during trial participation.&#xD;
&#xD;
          5. In addition to the above criteria, each group has specific inclusion criteria stated&#xD;
             below:&#xD;
&#xD;
               -  Group R+AD: Enrollment in this group requires that patients must have taken&#xD;
                  rasagiline and an antidepressant (SSRIs, SNRIs, St. John's wort and/or TCAs,&#xD;
                  regardless of indication) within 14 days of each other (or five weeks, if&#xD;
                  fluoxetine preceded rasagiline).&#xD;
&#xD;
               -  Group R: Enrollment in this group requires patients must have at least 2 months&#xD;
                  of rasagiline use.&#xD;
&#xD;
               -  Group AD: Patients must be taking an approved dopaminergic medication for PD.&#xD;
                  Enrollment in this group requires that patients must have at least 2 months of&#xD;
                  treatment with an antidepressant medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of rasagiline for any indication other than PD&#xD;
&#xD;
          2. Patients taking a monoamine oxidase inhibitor (MAOI) antidepressant and/or selegiline&#xD;
&#xD;
          3. Inability or unwillingness to request records of ER visits and/or hospitalizations&#xD;
             corresponding to the review period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Smith, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Neuroscience, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>August 6, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Serotonin Toxicity</keyword>
  <keyword>Rasagiline</keyword>
  <keyword>Antidepressants</keyword>
  <keyword>Chart Review</keyword>
  <keyword>Retrospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Serotonin Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

